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Fleroxacin is a new fluoroquinolone with a broad antibacterial spectrum and a 
serum half-life of about 8-12 h. Eighty percent of 400 isolates from complicated or 
hospital-acquired urinary tract infections were inhibited by a concentration of 
1 mg/l and 95% by 4 mg/I. As with other quinolones, fleroxacin is less active in acid 
urine (PH 5·4) than in Mueller-Hinton broth (PH 7·4). 
In 12 healthy volunteers the concentrations of fleroxacin were measured in 
plasma and seminal and prostatic fluid 2, 4 and 12 h after an oral dose of 400 mg. The 
mean plasma concentrations of three or four volunteers at each time were 4·2, 3·6 
and 1·2 mg/l, respectively. The corresponding prostatic fluid/plasma ratios were 
0·30, 0·27 and 1·96, respectively. By concomittant administration of ioxitalamic 
acid it could be demonstrated that in samples obtained 12 h after administration 
urinary contamination must be considered. Fleroxacin is concentrated in seminal 
fluid by a median ratio of 1·7. 
In 13 elderly patients the prostatic fluid and prostatic adenoma tissue 
concentrations were determined one to four hours following oral administration of 
400 mg. The concentrations in prostatic fluid were similar to those of volunteers. 
The tissue concentrations exceeded plasma concentrations by only about 10% 
(median). 
Fleroxacin is very active against isolates causing complicated UTI. 
Concentrations in seminal and prostatic fluid and prostatic adenoma tissue are 
sufficiently high to treat bacterial prostatitis or vesiculitis caused by susceptible 
bacterial strains. 
Introduction 
Fleroxacin (Ro 23-6240) is a new fluoroquinolone with a broad antibacterial spectrum 
and a serum half-life of about 8-12 h (Weidekamm, Stockel & Dell, 1987). 
Since resistant strains are frequently found in complicated or hospital-acquired 
urinary tract infections (UTI) (Naber et al., 1987), the in-vitro activity of fleroxacin 
was determined against isolates causing complicated UTIs in urological patients. In 
addition, in healthy volunteers the concentrations of fleroxacin were determined in 
seminal ,and prostatic fluid and in elderly patients undergoing transurethral resection 
of the prostate (TUR-P) in prostatic fluid and prostatic adenoma tissue. 
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Material and methods 
In-vitro study 
Isolates cultured from the urine of 400 inpatients with complicated or hospital-
acquired UTIs (~105 cfu/ml in two specimens within 48 h) were stored on nutrient 
agar. Only first isolates from patients with infections caused by single strains during 
hospitalization were used in the study. The MIC's of fleroxacin were determined by the 
agar dilution technique with serial twofold dilutions of the antibiotics in Mueller-
Hinton agar (Merck, Darmstadt, West Germany). Cultures were inoculated with 104 
cfu by a multipoint inoculator (Dynatech, Denkendorf, West Germany). After 18 h 
incubation at 37°C the MIC was determined as the lowest concentration of antibiotic 
inhibiting visible growth ( < 10 cfu). 
The bacteria studied were about one-third each of Escherichia coli, other Gram-
negative strains, and Gram-positive strains (mainly Streptococcus faecalis and 
Staphylococcus epidermidis). For seven selected strains of different species MICs of 
fleroxacin, norfloxacin and ofloxacin were also determined by a broth dilution method 
in Mueller-Hinton broth (pH 7·4) and urine (pH 5-4) in micro titre plates (Hoffmann-
La Roche, Basel, Switzerland). 
Study in volunteers 
In twelve healthy volunteers with a mean age 27·1 ±2·7 years (mean±s.D.), a mean 
body weight of 76·7±4·4kg (mean±s.D.) and a mean height f 180·5±5·1cm 
(mean ± S.D.) concentrations of fleroxacin were measured in plasma, prostatic and 
seminal fluid. All volunteers except one, were non-smokers. The subjects fasted for 
12 h before and 4 h after administration. In each volunteer sampling of prostatic fluid 
by massage of the prostate was followed by sampling of seminal fluid by masturbation 
at 2 h (group I, n = 4), 4 h (group II, n = 4), and 12 h (group III, n = 4), respectively, 
after oral administration of 400 mg fleroxacin. As a marker for urinary contamination 
of prostatic fluid 2·5 g of ioxitalamic acid (5 ml of Telebrix 300 Byk Gulden, 
Konstanz, West Germany) was given intravenously. In groups I and II ioxitalamic acid 
was given concomitantly with fleroxacin. Subjects were not allowed to void urine 
before samples were taken. In group III ioxitalamic acid was given 8 hours after 
fleroxacin. Subjects were instructed to void urine before prostatic fluid (12 h after 
administration of fleroxacin) was obtained. 
Blood samples were taken by a scalp vein needle prior to drug administration and at 
intervals up to 12 h. Samples were immediately centrifuged and stored at - 30° 
(protected against light) until analysis. Concentrations in liquids were determined with 
a reversed phase HPLC-method. 
Study in patients 
Thirteen elderly patients aged 58-81 years (median 72 years) with body weight of 
49-86 kg (median 73 kg), height of 158-174 cm (median 170 cm), serum creatinine of 
0·8-1·4mg/dl (median 1·0mg/dl) and haemoglobin of 12·2-17·9g/dl (median 
14·7 g/dl) undergoing TUR-P were treated orally with fleroxacin 400 mg 1-4 h 
preoperatively for antibiotic prophylaxis. Simultaneously ioxitalamic acid (2'5 g) was 
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administered iv to monitor renal function (Naber et al., 1984). and as a marker of 
urinary contamination. 
Immediately prior to TUR-P, prostatic fluid was obtained by prostatic massage. 
During the operation tissue samples of the two lateral and the median lobes of the 
prostate were collected for determination of tissue concentrations. Venous blood 
samples were taken prior to administration of fleroxacin and at the time of sampling 
the tissues. All samples were stored at - 70°C until analysis (HPLC). Tissue samples 
were homogenized (Sharpe & Jackson, 1972) prior to analyis. 
Results 
In-vitro study 
Eighty percent of the 400 strains were inhibited by 1 mg/l of fleroxacin and 95% by 
4 mg/l (Table I). In general, fleroxacin was more active against Gram-negative than 
Gram-positive strains (Table I). Only one strain of Pseudomonas aeruginosa, one strain 
each of coagulase negative and positive staphylococci, ten strains of Str. faecalis and 
five strains of streptococci (not group D) showed MICs greater than 4 mg/l. In urine 
(pH 5·4) all three quinolones were less active than in Mueller-Hinton broth (Table II) 
depending on the bacterial species. It was most marked with Proteus mirabilis because 
owing to its urease activity the urine becomes alkaline during incubation. 
Study in volunteers 
The concentrations of fleroxacin in plasma, in prostatic fluid and seminal fluid are 
shown in Figures 1 and 2. Fleroxacin was quickly absorbed in all 12 volunteers and 
showed a maximum plasma concentration of 5·42±1-41 mg/l after 1·3±0·78 h. The 
Table II. MIC of fleroxacin, norfloxacin and ofloxacin for seven strains of different species in 
Mueller-Hinton broth (pH 7-4) and acid urine (pH 5·4) 
Incubation Minimal inhibitory 
(20 h, 3rC) concentration (MIC) 
prior after fleroxacin norfloxacin ofloxacin 
Clinical Isolate Medium pH pH (mg/I) (mgjI) (mg/I) 
E. coli M-H 7-4 7·7 ~0'03l ~0·031 ~0·031 
Urine 5·4 5·8 0·063 0·125 0·125 
Pro mirabilis M-H 7-4 8·0 0·063 ~0·031 0·063 
Urine 5·4 8·0 8 8 32 
K. pneumoniae M-H 7-4 7·2 0·063 0·063 0·063 
Urine 5·4 6·7 1 2 2 
Ps. aeruginosa M-H 7-4 8·0 1 0·25 0·5 
Urine 5·4 6·7 4 4 4 
Ent. sakazakii M-H 7-4 8·0 0·063 ~0'031 0·031 
Urine 5·4 6·2 0·25 0·5 0·5 
Str. faecalis M-H 7-4 7·5 1 2 2 
Urine 5-4 5·8 0·125 8 4 
Staph. aureus M-H 7-4 7·2 0·5 0·5 0·25 
Urine 5-4 7·0 0·5 1 0·5 
M-H. Mueller-Hinton broth. 
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Figure 1. Mean plasma (0) and individual prostatic fluid CA.) concentrations of fleroxacin in 12 healthy 
volunteers after oral administration of 400 mg. 
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Figure 2. Mean plasma (.) and individual seminal fluid (+ 0 fraction 1; .0 fraction 2) (split ejaculate) 
concentrations of fleroxacin in 12 healthy volunteers after oral administration of 400 mg. 
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Figure 3_ Plasma concentrations of fleroxacin in 13 elderly patients undergoing TUR of the prostate after 
oral administration of 400 mg. 
concentrations decreased to 4-17 ± 0-60 mg/] at 2 h, to 3-44 ± 41 mg/1 at 4 h, and to 
1·76 ± 0-21 mg/I at 12 h after administration. 
The prostatic fluid concentrations in groups I and II (n = 8) were between 0·84 and 
1·69 mg/I (median 1·00 mg/I, average I-II mg/I) without a significant difference 
between the two groups_ The fluid/plasma ratios ranged between 0-22 and 0-37 
(median 0-28, average 0-29). At 12 h (group III, n = 3) the prostatic fluid 
concentrations were between 1-40 and 4·18 mg/l (median 3-39 mg/I, 2-99 mg/I) with 
fluid/plasma ratios between 0-89 and 2-76 (median 2·24, average 1·96)_ 
The measurement of ioxitalamic acid in prostatic fluid of groups I and II showed 
concentrations below the limit of detection (2 mg/I) except for one subject (6-2 mg/I)_ 
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Figure 4. Prostatic fluid concentrations of fieroxacin in nine elderly patients undergoing TUR of prostate 
after oral administration of 400 mg. 
7 
6 
~ 
...... 
0-
E 
c 5 
.~ 
~ 
c 
.. 
u 
4 c 
0 
u .. 
. ; 
0 3 
E 
0 
c: 
'" 
" 0 2 u 
§ 
.. 
0 
ci: 
o 
Fleroxacin concentrations in seminal and prostatic fluid 
1<> 
i 
2<> 
Time (h) 
I 
I~~I 
fllllll! 
2·5 
I 
4·0 
205 
Figure 5. Prostatic adenoma tissue concentrations of fleroxacin in 10 elderly patients undergoing TUR of 
the prostate after oral administration of 400 mg. 
In volunteers of group III, however, the concentrations were between 141 and 
445 mg/l (median 233 mg/l) confirming that ioxitalamic acid is a reliable marker for 
urinary contamination. 
Seminal fluid was collected as split ejaculate in two portions. Concentrations 
between fraction 1 and fraction 2 did not differ significantly. The following values refer 
to fraction 2. The concentrations of fleroxacin in seminal fluid (Figure 2) in groups I 
and II were between 3·95 and 8·61 mg/l (median 5·80 mg/l) without a statistical 
difference between the two groups. The corresponding fluid /plasma ratios ranged from 
0·9 to 2·3 (median 1'7). The concentrations of fleroxacin in group III were clearly 
lower, namely between 1·96 and 3·11 mg/l (median 2·89 mg/I). The fluid/plasma ratios, 
however, were similar to those in groups I and II, namely between 1·6 and 1·8 (median 
1·7). The concentrations of ioxitalamic acid in seminal fluid did not indicate significant 
urinary contamination. 
Study in patients 
The plasma concentrations of fleroxacin are shown in Figure 3. In 12 patients the 
concentrations after I and 4 h ranged from 5·5 to 2·4 mg/I (median 3·7 mg/I). In one 
patient a plasma concentration of 0·44 mg/l was found after 2 h. In nine patients 
concentrations of prostatic fluid could be obtained (Figure 3). The concentrations 
ranged from 0·53 to 4·15 mg/l (median 1·67 mg/l) with fluid/plasma ratios ranging 
from 0·21- 2·44 (median 0·37). If a prostatic secretion/plasma ratio for ioxitalamic acid 
of greater than 1·0 is accepted as an indication for urinary contamination, only five 
patients were probably not contaminated. In these five patients the prostatic fluid 
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concentrations ranged from O' 53-4·15 mg/I (median 1·71 mg/I) with fluid/plasma 
ratios ranging from 0·21 to 0·93 (median 0·31). 
The concentrations in prostatic tissue I· 5-4'0 h after oral administration of 400 mg 
of fleroxacin are shown in Figure 5. In 10 patients the tissue concentrations ranged 
from 2·98 mg/kg to 6·82 mg/kg (median 4·35 mg/kg). In one patient a tissue 
concentration of 0·58 mg/kg with a corresponding plasma concentration of 0·44 mg/I 
was found. The tissue/plasma ratios in all II patients ranged from 1·00 to 1·92 (median 
1'10). In ten patients the ratios were between 1·00 and 1·32 (median 1'09). 
Discussion 
Fleroxacin is highly active against Gram-negative and Gram-positive strains causing 
complicated and/or nosocomial UTI. As other quinolones (Shah, Ottrad & Stille, 
1983; Shah, Schiitzeichel & Stille, 1984) its activity is diminished in acid urine 
depending on the bacterial species. The urinary concentrations, however, are several 
folds higher than the MIC in urine. 
The concentrations in prostatic fluid following an oral dose of 400 mg are 
sufficiently high to treat fully sensitive strains (MIC :( I mg/l). Since volunteers had to 
void urine between 4 and 12 h after the oral dose of fleroxacin, urinary contamination 
of prostatic fluid collected at 12 h after administration could be demonstrated. 
Therefore, concentrations measured in prostatic fluid after voiding are not valid and 
this applies to all studies performed in the past. The prostatic fluid concentrations 
measured in elderly patients were in a similar range if the same precautions are taken. 
Since concentrations in prostatic fluid can only be measured before voiding, the time 
after administration is limited. Up to 4 h it could not be demonstrated that fleroxacin 
is concentrated in prostatic fluid. 
The concentrations of fleroxacin in seminal fluid, in which urinary contamination 
does not playa major role, exceeded plasma concentrations by a median ratio of 1·7. 
Therefore, it can be concluded that fleroxacin is concentrated in seminal fluid. 
The concentrations of fleroxacin in prostatic adenoma tissue exceeded plasma 
concentrations by about 10%. 
From these in-vitro and in-vivo studies it can be concluded that fleroxacin is active 
against almost the total spectrum of bacteria causing complicated and/or hospital 
acquired UTIs. In bacterial prostatitis and vesiculitis concentrations of fleroxacin in 
seminal and prostatic fluid and in prostatic adenoma tissue are sufficiently high to treat 
infections with susceptible strains. 
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